Allied Health Hub Morayfield
Brisbane, Queensland, 4506, Australia
Location status: Recruiting
Location contact
Dr Christopher Geoffrey Moller
CONTACT
Dr Christopher Geoffrey Moller
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07514416
This study is being done to check how safe and comfortable LCFA-01 is when used inside the vagina. LCFA-01 is a natural product that contains oleic acid, and it comes as a soft gel capsule that participants will place in the vagina using their fingers.
The main purpose of the study is to make sure the product is safe and does not cause any problems or discomfort. The study will also measure how much of the product stays in the vagina and whether any of it enters the bloodstream. This helps researchers understand how the body absorbs and handles the product.
Finally, the study will also look at early signs of how the product might affect the natural bacteria in the vagina.
In the future, LCFA-01 may be used to treat bacterial vaginosis (BV).
Interested in participating?
Request Info18 year–40 year
Female
Interventional
Phase 1
Brisbane, Queensland, 4506, Australia
Location status: Recruiting
Dr Christopher Geoffrey Moller
CONTACT
Dr Christopher Geoffrey Moller
PRINCIPAL_INVESTIGATOR
This study is testing a new vaginal product called LCFA-01 for the first time in humans. The goal is to see:
Up to 30 healthy adult women who are 18 years to 40 years of age and who are not pregnant & not in menopause.
Women first go through a "Screening period" lasting up to 35 days. Doctors make sure they are healthy and can join the study.
The whole study period lasts 2 weeks:
Week 1: Using the product
Women use the vaginal product once a day for 7 days. Day 1 and Day 2: They use it at the clinic, so doctors can watch closely for safety.
Day 3 to Day 7: They use it at home.
Women also take their own vaginal swab samples every day at home. During the first week, they take the swab before using the product.
Week 2: No product
Women stop using the product but continue to self-swab at home. They come back for a check-up at the end of this week.
There will be 2 groups (cohorts), each trying a different amount of LCFA-01:
In each group, 2 out of 3 women get LCFA-01
1 out of 3 gets a placebo (a harmless, inactive product)
This helps researchers compare effects.
Only 2 women (one gets LCFA-01, one gets placebo) are treated first in each group.
Doctors watch them for 24 hours. If everything looks safe, the rest of the women in that group can begin the study.
Are there any side effects? Is the product safe and comfortable to use? Does any of the product get into the bloodstream? How long does the product stay in the vagina? How does it affect the vaginal environment?
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
receptive oral sex anal sex vaginal sex toys
Exclusion criteria
a. Serious diseases of the vagina, cervix, or uterus, such as:
b. Uncontrolled genital herpes, meaning they had at least one active outbreak in the past 6 months.
c. Serious health problems such as: heart disease or a past heart attack chronic lung disease (like COPD) chronic kidney failure severe liver disease (cirrhosis) or any other serious condition that the study doctor believes would make it unsafe to join the study.
d. Any condition that would require using steroid medicines inside the genital area during the study. (Steroid creams used on the skin, inhalers, or nose sprays are allowed.) e. A yeast infection (vulvovaginal candidiasis) found during Screening. f. Repeated episodes of bacterial vaginosis (BV), meaning two or more episodes in the past year.
Hashimoto's thyroid disease Pernicious anemia Addison's disease Rheumatoid arthritis Lupus Multiple sclerosis Myasthenia gravis Grave's disease Celiac disease Psoriasis Sarcoidosis Scleroderma Diabetes (Type 1)
This includes:
vaginal douching using products to clean, wash, dry, or "freshen" the vagina
LCFA-01 Drug Product is a soft gelatin capsule, containing oleic acid at 2 dosage strengths (200 mg and 400 mg).
LCFA-01 Placebo is a soft gelatin capsule, of which the composition is similar to that of LCFA-01 Drug Product, but without the active pharmaceutical ingredient.
Time frame: Day 1 to Day 14
Time frame: Baseline, Day 2, Day 8, Day 10, Day 14
Time frame: Baseline, Day2, Day 8, Day 10, Day 14
Time frame: Baseline, Day 1, Day 2, Day 8, Day 10
Time frame: Baseline to Day 14
Time frame: Baseline to Day 14
Time frame: Baseline to Day 14
Time frame: Baseline to Day 14
Time frame: Baseline to Day 14
Time frame: Baseline to Day 14
Time frame: Baseline to Day 14
Time frame: Baseline to Day 14
Time frame: Baseline to Day 14
Time frame: On Day 1, 2, 8, 10
Time frame: Day 1, 2, 8, 10, 14
Time frame: On Day 1, 2, 8, 10
Time frame: On Day 1, 2, 8, 10
Contact information is provided by the study sponsor or research team.
Dr Caroline Mitchell, MD, MPH
CONTACT
Dr Douglas Kwon
CONTACT
Massachusetts General Hospital
Other
A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LCFA-01, an Intravaginal Product, in Healthy Participants for Bacterial Vaginosis Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.